Analyst Ratings for Biogen (BIIB)
BIIB Rating Summary
BIIB Price Target Summary
- Highest: $250.00 (Oppenheimer)
- Lowest: $143.00 (HSBC)
- Average: $206.41
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$206.41 (+11.7%)
* Over Last 12-Mos
Rating Score: 4.9 / 10
Percentile Rank: 48%
Avg. $ Target:
$206.41 (+11.7%)
* Over Last 12-Mos
Rating Score: 4.9 / 10
Percentile Rank: 48%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/19/2026 | Barclays | Carter Gould | New Coverage | Equalweight (N/A) |
185.00 (N/A) |
194.13 (184.87) |
-4.77% | Details |
| 1/7/2026 | UBS | Michael Yee | New Coverage | Neutral (N/A) |
185.00 (130.00) |
174.63 (184.87) |
5.86% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
